FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, has been selected to participate in Innovate UK's Global Business Innovation Programme (GBIP) focusing on Antimicrobial Resistance.
This year, FluoretiQ will join a delegation representing cutting-edge UK diagnostics, therapeutics, preventatives, and vaccines, headed to Switzerland.
Innovate UK's GBIP supports innovative SMEs in exploring global markets to accelerate business growth. Each GBIP, tailored to specific markets and technology sectors, includes up to 15 ambitious UK businesses looking to expand globally. The program aims to help these businesses explore future opportunities and understand what it takes to succeed on the global stage.
GBIP offers detailed market knowledge, cultural insight, and valuable introductions and connections, opening doors that SMEs might struggle to access independently. Each business is supported by an Innovate UK EDGE innovation and growth specialist to maximize the program's potential and beyond.
FluoretiQ Ltd, born at the Quantum Technology Enterprise Centre (QTEC) in Bristol, envisions revolutionizing bacteria identification. Their innovation—a rapid and straightforward bacteria diagnostic test—utilizes innovative probes and powerful fluorescence sensors to detect and identify bacteria in physiological samples.